Omeros (OMER) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.10

Estimate

-$0.33

Surprise

+128.8%

Revenue (period 2026-06-30)

$28.5M

Score today

5.5/10

Revenue source: xbrl.

Omeros (OMER) beat the -$0.33 estimate with diluted EPS of $0.10 — a large 128.8% upside surprise.

• 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga, 2026-08-13
• Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday — benzinga, 2026-08-13
• 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga, 2026-08-13

TrendMatrix currently rates OMER Sell at 5.5/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +128.8% surprise compares with a +111.7% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$17.35

Price target

$28.05

Stop

$16.13

Upside to target

+61.7%

Reward-to-risk

6.4:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.24B

P/E (fwd)

15.0

P/E (ttm)

10.6

52-week range

$3.94–$19.65

Off 52-week high

11.7%

RSI (14)

42

Volume vs avg

1.34×

Score today

5.5/10